Skip to main content

Table 3 Most common adverse events during TB treatment and treatment outcomes among HIV-infected TB patients, stratified by markers for viral hepatitis infections.

From: Viral hepatitis and HIV-associated tuberculosis: Risk factors and TB treatment outcomes in Thailand

Adverse events and treatment outcomes

All patients (n = 769)

Non-reactive for HBsAg and anti-HCV (n = 472)

Reactive for

Unknown (n = 17)

   

Only HBsAg (n = 43)

Only anti-HCV (n = 210)

HBsAg and anti-HCV (n = 27)

 
 

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Adverse events

      

Rash

116 (15)

69 (15)

7 (16)

32 (15)

4 (15)

4 (24)

Immune reconstitution inflammatory syndrome*

16 (7)

12 (7)

0 (0)

2 (6)

1 (13)

1 (100)

Liver disease

41 (5)

23 (5)

3 (7)

12 (6)

2 (7)

1 (6)

Diarrhea

36 (5)

22 (5)

2 (5)

7 (3)

2 (7)

3 (18)

Pneumonia including PCP

30 (4)

15 (3)

2 (5)

11 (5)

1 (4)

1 (6)

Meningitis

20 (3)

11 (2)

2 (5)

6 (3)

1 (4)

0 (0)

HIV wasting syndrome

19 (3)

15 (3)

0 (0)

1 (1)

1 (4)

2 (12)

Cryptococcosis

16 (2)

8 (2)

0 (0)

8 (4)

0 (0)

0 (0)

Herpes zoster

12 (2)

5 (1)

2 (5)

4 (2)

1 (4)

0 (0)

Recurrent upper respiratory infections or sinusitis

7 (1)

5 (1)

0 (0)

0 (0)

2 (7)

0 (0)

Treatment outcomes

      

Cure

210 (27)

133 (28)

7 (16)

63 (30)

6 (22)

1 (6)

Complete

283 (37)

190 (40)

16 (37)

65 (31)

9 (33)

3 (18)

Failure

6 (1)

3 (1)

1 (2)

2 (1)

0 (0)

0 (0)

Die

130 (17)

72 (15)

5 (12)

37 (18)

7 (26)

9 (53)

Default

65 (9)

34 (7)

8 (19)

20 (10)

1 (4)

2 (12)

Transfer out

70 (9)

37 (8)

5 (12)

22 (11)

4 (15)

2 (12)

On treatment

5 (1)

3 (1)

1 (2)

1 (1)

0 (0)

0 (0)

  1. TB, tuberculosis; HIV, human immunodeficiency virus; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; PCP, pneumocystis carinii pneumonia.
  2. *Among 237 patients eligible to be evaluated only.